

Recombinant Human TNFSF7/CD27 Ligand/CD70 Protein

Catalog No.: RP01720 Recombinant

Sequence Information

Species Gene ID Swiss Prot Human 970 P32970

Tags N-6His

Synonyms

CD27L; LPFS3; CD27-L; CD27LG; TNFSF7; TNLG8A;CD70

Product Information

Source Purification HEK293 cells ≥ 95 % as

determined by SDS-

PAGE.

Calculated MW Observed MW

17.98 kDa 25 kDa

Endotoxin

< 1 EU/µg of the protein by LAL method.

Formulation

Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.

Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

a	400-999-6126
\bowtie	cn.market@abclonal.com.cn
$\overline{\bullet}$	www.abclonal.com.cn

Background

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T- and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.

Basic Information

Description

Recombinant Human TNFSF7/CD27 Ligand/CD70 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln39-Pro193) of human CD70/TNFSF7/CD27 Ligand (Accession #NP_001243.1) fused with and a 6×His tag at the N-terminus.

Bio-Activity

Measured by its binding ability in a functional ELISA.Immobilized Human TNFSF7 (Catalog: RP01720) at 2 μ g/mL (100 μ L/well) can bind Human TNFRSF7 (Catalog: RP01358) with a linear range of 0.2-82 ng/mL.


Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20 $^{\circ}$ C for 3 months, at 2-8 $^{\circ}$ C for up to 1 week.

Avoid repeated freeze/thaw cycles.

Validation Data



Recombinant Human TNFSF7/CD27 Ligand/CD70 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Immobilized Human TNFSF7 (Catalog: RP01720) at 2 μ g/mL (100 μ L/well) can bind Human TNFRSF7 (Catalog: RP01358) with a linear range of 0.2-82 ng/mL.